[Federal Register Volume 74, Number 135 (Thursday, July 16, 2009)]
[Notices]
[Pages 34559-34560]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-16874]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Meeting of the Uniform Formulary Beneficiary Advisory Panel

AGENCY: Department of Defense, Assistant Secretary of Defense (Health 
Affairs).

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: Under the provisions of the Federal Advisory Committee Act of 
1972 (Title 5, U.S. Code (U.S.C.)., Appendix, as amended) and the 
Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended) the 
Department of Defense announces the following Federal Advisory 
Committee Meeting of the Uniform Formulary

[[Page 34560]]

Beneficiary Advisory Panel (hereafter referred to as the Panel).

DATES: July 30, 2009 (10 a.m.-4 p.m.).

ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue, NW., 
Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: Lieutenant Colonel Thomas Bacon, 
Designated Federal Officer, Uniform Formulary Beneficiary Advisory 
Panel. Skyline 5, Suite 810, 5111 Leesburg Pike, Falls Church, VA 
22041-3206; Telephone: (703) 681-2890; Fax: (703) 681-1940; E-mail 
Address: <a href="/cdn-cgi/l/email-protection#31735041435440445442454271455c501f5e42551f5c585d"><span class="__cf_email__" data-cfemail="5b193a2b293e2a2e3e282f281b2f363a7534283f75363237">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: 
    Purpose of Meeting: The Panel will review and comment on 
recommendations made to the Director, TRICARE Management Activity, by 
the Pharmacy and Therapeutics Committee regarding the Uniform 
Formulary.
    Meeting Agenda: Sign-In; Welcome and Opening Remarks; Public 
Citizen Comments; Scheduled Therapeutic Class Reviews-Designated Newly 
Approved Drugs; Panel Discussions and Vote, and comments following each 
therapeutic class review.
    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 
Title 41, Code of Federal Regulations (CFR), Section 102-3.140 through 
102-3.165, and the availability of space this meeting is open to the 
public. Seating is limited and will be provided only to the first 220 
people signing in. All persons must sign in legibly.
    Administrative Work Meeting: Prior to the public meeting the Panel 
will conduct an Administrative Work Meeting from 8 a.m. to 10 a.m. to 
discuss administrative matters of the Panel. The Administrative Work 
Meeting will be held at the Naval Heritage Center, 701 Pennsylvania 
Avenue, NW., Washington DC 20004. Pursuant to 41 CFR 102-3.160, the 
Administrative Work Meeting will be closed to the public.
    Written Statements: Pursuant to 41 CFR 102-3.105(j) and 102-3.140, 
the public or interested organizations may submit written statements to 
the membership of the Panel at any time or in response to the stated 
agenda of a planned meeting. Written statements should be submitted to 
the Panel's Designated Federal Officer; the Designated Federal 
Officer's contact information can be obtained from the General Services 
Administration's Federal Advisory Committee Act Database-https://www.fido.gov/facadatabase/public.asp.
    Written statements that do not pertain to the scheduled meeting of 
the Panel may be submitted at any time. However, if individual comments 
pertain to a specific topic being discussed at a planned meeting then 
these statements must be submitted no later than five business days 
prior to the meeting in question. The Designated Federal Officer will 
review all submitted written statements and provide copies to all the 
committee members.
    Public Comments: In addition to written statements, the Panel will 
set aside 1 hour for individuals or interested groups to address the 
Panel. To ensure consideration of their comments, individuals and 
interested groups should submit written statements as outlined in this 
notice, but if they still want to address the Panel then they will be 
afforded the opportunity to register to address the Panel. The Panel's 
Designated Federal Officer will have a ``Sign Up Roster'' available at 
the Panel meeting, for registration on a first-come, first-serve basis. 
Those wishing to address the Panel will be given no more than 5 minutes 
to present their comments, and at the end of the 1 hour time period no 
further public comments will be accepted. Anyone who signs up to 
address the Panel but is unable to do so due to the time limitation may 
submit their comments in writing; however, they must understand that 
their written comments may not be reviewed prior to the Panel's 
deliberation. Accordingly, the Panel recommends that individuals and 
interested groups consider submitting written statements instead of 
addressing the Panel.

    Dated: July 10, 2009.
Morgan E. Frazier,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. E9-16874 Filed 7-15-09; 8:45 am]
BILLING CODE 5001-06-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>